Clinical trials: ANCA-associated Primary Necrotizing Vasculitides
ANCA-associated Primary Necrotizing Vasculitides
Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
The purpose of this study is to assess whether rosuvastatin could reduce the subclinical markers of atherosclerosis and the incidence of major cardiovascular events in patients with primary necrotizing vasculitides.
- Trial name
- STATVAS (NCT02117453)
- Testing
- Rosuvastatin
- Where
- France
- Volunteers
- 121 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris